Published in J Clin Oncol on February 03, 2014
ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol (2015) 3.19
Collection and use of family history in oncology clinics. J Clin Oncol (2014) 1.03
Population Landscape of Familial Cancer. Sci Rep (2015) 0.98
Important differences between a triage pedigree and risk assessment. J Clin Oncol (2014) 0.97
Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol (2016) 0.83
Protocol for the "Implementation, adoption, and utility of family history in diverse care settings" study. Implement Sci (2015) 0.80
An internal performance assessment of CancerGene Connect: an electronic tool to streamline, measure and improve the genetic counseling process. J Genet Couns (2014) 0.78
Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women. Springerplus (2014) 0.78
Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract (2017) 0.77
Clinically relevant lessons from Family HealthLink: a cancer and coronary heart disease familial risk assessment tool. Genet Med (2014) 0.76
Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review. Oncologist (2016) 0.75
Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics. J Clin Oncol (2015) 0.75
Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med (2016) 0.75
A model for patient-direct screening and referral for familial cancer risk. Fam Cancer (2016) 0.75
Contribution of extended family history in assessment of risk for breast and colon cancer. BMC Fam Pract (2016) 0.75
Genetics educational needs in China: physicians' experience and knowledge of genetic testing. Genet Med (2014) 0.75
Self-reported cancer family history is a useful tool for identification of individuals at risk of hereditary cancer predisposition syndrome at primary care centers in middle-income settings: a longitudinal study. Genet Mol Biol (2016) 0.75
The History and Physical in Cancer Care: A Primer for the Oncology Advanced Practitioner. J Adv Pract Oncol (2015) 0.75
Incorporating genetic counseling into clinical care for children and adolescents with cancer. Future Oncol (2016) 0.75
Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases. Int J Colorectal Dis (2017) 0.75
Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer. Jpn J Clin Oncol (2017) 0.75
Placing negative multi-gene panel results into clinical context. Fam Cancer (2017) 0.75
AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS). Arch Gynecol Obstet (2017) 0.75
Initial clinical validation of Health Heritage, a patient-facing tool for personal and family history collection and cancer risk assessment. Fam Cancer (2016) 0.75
Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management. Am J Gastroenterol (2017) 0.75
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med (2003) 3.94
Reconsidering the family history in primary care. J Gen Intern Med (2004) 3.50
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology (2001) 2.63
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol (1996) 2.32
Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet (2002) 2.29
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
New standards and enhanced utility for family health history information in the electronic health record: an update from the American Health Information Community's Family Health History Multi-Stakeholder Workgroup. J Am Med Inform Assoc (2008) 2.14
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol (2009) 2.02
2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol (2009) 1.97
Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns (2011) 1.92
Accuracy of reporting of family history of colorectal cancer. Gut (2004) 1.92
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol (2012) 1.86
Systematic review: family history in risk assessment for common diseases. Ann Intern Med (2009) 1.70
Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol (2009) 1.62
Extending the phenotypes associated with DICER1 mutations. Hum Mutat (2011) 1.61
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer (2011) 1.52
Accuracy of family history of cancer: clinical genetic implications. Eur J Hum Genet (2000) 1.47
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Juvenile polyposis syndrome. World J Gastroenterol (2011) 1.26
Bias in the reporting of family history: implications for clinical care. J Genet Couns (2012) 1.13
Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract (2008) 1.13
Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test (2004) 1.09
Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res (2010) 1.08
Educational needs about cancer family history and genetic counseling for cancer risk among frontline healthcare clinicians in New York City. Genet Med (2011) 1.02
Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2012) 1.00
Hereditary breast cancer in Jews. Fam Cancer (2004) 0.99
Hereditary breast and ovarian cancer syndrome. Gynecol Oncol (2009) 0.99
Family history: still relevant in the genomics era. Cleve Clin J Med (2012) 0.98
Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf) (2013) 0.97
Inherited susceptibility for pediatric cancer. Cancer J (2005) 0.95
Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J (2009) 0.92
10 rare tumors that warrant a genetics referral. Fam Cancer (2013) 0.84
Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children's Hospital Los Angeles (CHLA) experience, 1991-2010. Pediatr Blood Cancer (2011) 0.81
Do people really know what makes a family history of cancer? Health Expect (2012) 0.80
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol (2006) 11.07
ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res (2013) 9.31
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol (2003) 6.66
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol (2011) 4.64
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet (2012) 4.45
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 3.92
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst (2009) 3.89
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol (2007) 3.85
American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol (2009) 3.73
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology (2008) 3.35
Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
Microduplication 22q11.2, an emerging syndrome: clinical, cytogenetic, and molecular analysis of thirteen patients. Am J Hum Genet (2003) 3.01
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA (2004) 2.99
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
The state of cancer care in america, 2015: a report by the american society of clinical oncology. J Oncol Pract (2015) 2.90
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA (2006) 2.73
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med (2016) 2.72
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2014) 2.57
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med (2013) 2.54
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol (2011) 2.51
Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol (2010) 2.50
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst (2012) 2.44
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol (2013) 2.43
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
The genetic family history as a risk assessment tool in internal medicine. Genet Med (2003) 2.35
MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology (2004) 2.35
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 2.33
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut (2010) 2.30
Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet (2002) 2.27
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg (2005) 2.19
The Mayo Clinic Biobank: a building block for individualized medicine. Mayo Clin Proc (2013) 2.18
American Society of Clinical Oncology: Policy for relationships with companies. J Clin Oncol (2013) 2.18
Consensus conference on breast conservation. J Am Coll Surg (2006) 2.17
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol (2010) 2.16
Recommendations for clinical trials of off-label drugs used to treat advanced-stage cancer. J Clin Oncol (2012) 2.15
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol (2010) 2.14
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol (2007) 2.09
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02